Live Breaking News & Updates on R Sanders Williams

Stay updated with breaking news from R sanders williams. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Barclays Downgrades Amgen (NASDAQ:AMGN) to Underweight

Amgen (NASDAQ:AMGN – Get Rating) was downgraded by equities researchers at Barclays from an “equal weight” rating to an “underweight” rating in a research report issued on Monday, MarketBeat Ratings reports. They currently have a $234.00 target price on the medical research company’s stock. Barclays‘s price target indicates a potential downside of 13.99% from the […] ....

R Sanders Williams , Robert Eckert , Piper Sandler , Robertw Baird , Securities Exchange Commission , Asset Dedication , Quilter Plc , Indexiq Advisors , Group Ltd , Advisor Group , Amgen Inc , Royal Bank , Get Rating , Marketbeat Ratings , Director Robert Eckert , Exchange Commission , Directorr Sanders Williams , Amgen Daily , Nasdaq Amgn , Barclays Plc ,

Sawgrass Asset Management LLC Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Sawgrass Asset Management LLC purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 77,946 shares of the medical research company’s stock, valued at approximately $18,849,000. Amgen comprises approximately 2.0% of […] ....

R Sanders Williams , Robert Eckert , Securities Exchange Commission , Prudential Plc , Motley Fool Asset Management , Sawgrass Asset Management , Amgen Inc , Equitable Holdings Inc , Royal Bank , Get Rating , Fool Asset Management , Alternative Capital , Director Robert Eckert , Exchange Commission , Directorr Sanders Williams , Stock Down , Visit Holdingschannel , Amgen Daily , Nasdaq Amgn , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Amgen (NASDAQ:AMGN) Price Target Increased to $290.00 by Analysts at Oppenheimer

Amgen (NASDAQ:AMGN – Get Rating) had its target price increased by Oppenheimer from $285.00 to $290.00 in a research note issued to investors on Wednesday morning, The Fly reports. Other equities analysts also recently issued research reports about the stock. StockNews.com upgraded shares of Amgen from a buy rating to a strong-buy rating in a […] ....

R Sanders Williams , Jonathanp Graham , Piper Sandler , Morgan Stanley , Securities Exchange Commission , Gryphon Financial Partners , Mission Creek Capital Partners Inc , Warren Averett Asset Management , Wells Fargo Company , Amgen Inc , Pacifica Partners Inc , Get Rating , Exchange Commission , Directorr Sanders Williams , Averett Asset Management , Creek Capital Partners , Financial Partners , Nasdaq Amgn , Boost Price Target , Oppenheimer Holdings Inc ,